Results of the IDEAL LM trial showed patients with left main coronary artery disease treated with Boston Scientific Corp.'s Synergy everolimus-eluting platinum-chromium stent with a biodegradable polymer fared equally well with short-duration dual antiplatelet therapy (DAPT) as patients treated with Abbott Laboratories Inc.'s Xience everolimus-eluting cobalt-chromium stent and a standard 12-month course of antiplatelet therapy.
Robert-Jan Van Geuns, from Erasmus Medical Center in Rotterdam, reported the results on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco. IDEAL LM was conducted at 29 sites across six countries between 2014 and 2016. Investigators randomized 818 patients to intervention with Synergy and four months DAPT or Xience and 12 months DAPT
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?